MW
Therapeutic Areas
Celon Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KAND567 | Prevention of chemotherapy-induced cardiotoxicity | Phase II |
| CEP-40783 | Rheumatoid Arthritis | Phase II |
| CEL-101 (C-122) | Insomnia | Phase II |
| CEL-202 | Solid Tumors | Phase I/II |
| CEL-301 | Undisclosed Oncology | Preclinical |